[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627633":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":36,"centralContacts":43,"locations":48,"responsibleParty":71,"collaborators":74,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":28,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":28,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Metronidazole","EXPERIMENTAL","14-day oral course",[13],"Drug: Metronidazole",{"label":15,"type":10,"description":11,"interventionNames":16},"Trimethoprim-sulfamethoxazole and Metronidazole",[17,13],"Drug: Trimethoprim-sulfamethoxazole (TMP\u002FSMX)",{"label":19,"type":10,"description":11,"interventionNames":20},"Amoxicillin-Clavulanate",[21],"Drug: Amoxicillin-Clavulanate (4:1 formulation)",[23,29,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Trimethoprim-sulfamethoxazole (TMP\u002FSMX)","8-10 mg\u002Fkg\u002Fday divided every 12 hours, with a maximum 160 mg\u002Fdose; dosing based on Trimethoprim",[15],null,{"type":24,"name":9,"description":30,"armGroupLabels":31,"otherNames":28},"Administered alone: 20-30 mg\u002Fkg\u002Fday divided every 8 hours, with a maximum 750 mg\u002Fdose\n\nCo-administered with Trimethoprim-sulfamethoxazole: 35-50 mg\u002Fkg\u002Fday divided every 8 hours, with a maximum 750 mg\u002Fdose",[9,15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"Amoxicillin-Clavulanate (4:1 formulation)","20-40 mg amoxicillin\u002Fkg\u002Fday divided every 8 hours, with maximum daily dose of 1,500 mg",[19],[37,40],{"name":38,"affiliation":5,"role":39},"Jeffrey R Donowitz, MD","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":42,"role":39},"Rashidul Haque, MBBS, PhD","International Centre for Diarrhoeal Disease Research, Bangladesh",[44],{"name":38,"role":45,"phone":46,"phoneExt":28,"email":47},"CONTACT","434-243-8824","jrd9d@virginia.edu",[49],{"facility":50,"status":51,"city":52,"state":28,"zip":28,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)","RECRUITING","Dhaka","Bangladesh","BD",{"type":56,"coordinates":57},"Point",[58,59],90.40744,23.7104,{"lat":59,"lon":58},[62,66,70],{"name":41,"role":45,"phone":63,"phoneExt":64,"email":65},"880-0171-3093859","3483","rhaque@icddrb.org",{"name":67,"role":45,"phone":68,"phoneExt":28,"email":69},"Tahsin Ferdous, MBBS, MPH","880-0171-6041188","tahsin.ferdous@icddrb.org",{"name":41,"role":39,"phone":28,"phoneExt":28,"email":28},{"type":39,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Jeffrey Donowitz, MD","Associate Professor",[75,78,79,81],{"name":76,"class":77},"National Institutes of Health (NIH)","NIH",{"name":42,"class":6},{"name":80,"class":6},"Virginia Commonwealth University",{"name":82,"class":77},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100627633","phase-2-comparative-efficacy-of-antibiotics-for-small-intestine-bacterial-overgrowth-in-bangladeshi-children-100627633",false,"NCT07451171","Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth","Inclusion Criteria:\n\n* Positive glucose hydrogen breath test (GHBT)\n* Weight-for-age Z score \\> -1\n* Length-for-age Z score \\> -1\n\nExclusion Criteria:\n\n* Presence of known chronic or congenital illness, including developmental delay\n* Presence of acute gastrointestinal illness in the preceding 14 days\n* Antibiotic use in the preceding 14 days\n* Previous adverse reaction to any of the three study medications or other drugs in the same antibiotic classes\n* Sibling previously enrolled in this study","ALL","1 Year","2 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98],"PHASE2","The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.",[101],"Small Intestine Bacterial Overgrowth",[103],"environmental enteric dysfunction","2026-05-01",{"date":106,"type":107},"2026-05-06","ACTUAL",{"date":109,"type":107},"2026-04-18",{"date":111,"type":95},"2026-09-01",{"name":5,"class":6},1]